Barriers to innovation in human rabies prophylaxis and treatment: A causal analysis of insights from key opinion leaders and literature

This study identifies barriers that were not previously described in this specific context, for example the competition for funding between medical and veterinary approaches. The results stress the existence of barriers beyond the limited return on investment and thereby explain why innovation in human rabies medication is lagging behind NTDs with a lower burden of disease. A re‐orientation on the full spectrum of barriers that hinder innovation in rabies prophylaxis and treatment is necessary to meet unmet societal and medical needs.

Source: Zoonoses and Public Health - February 28, 2017 Category: Infectious Diseases Authors: L. H. M. Burgwal, A. M. G. Neevel, C. A. C. M. Pittens, A. D. M. E. Osterhaus, C. E. Rupprecht, E. Claassen Tags: ORIGINAL ARTICLE Source Type: research